Clinical Trial Update: Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating two dose levels of quizartinib as maintenance therapy in FLT3-ITD-positive acute myeloid leukemia patients in complete remission.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Quizartinib (Quizartinib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Acute Myeloid Leukemia, Leukemia | Phase 2 | Status: RECRUITING